title: Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function.
abstract: Kinins are vasoactive oligopeptides generated upon proteolytic cleavage of low and high molecular weight kininogens by kallikreins. These peptides have a well established signaling role in inflammation and homeostasis. Nevertheless, emerging evidence suggests that bradykinin and other kinins are stored in the central nervous system and may act as neuromediators in the control of nociceptive response. Here we show that the kinin-B2 receptor (B2BKR) is differentially expressed during in vitro neuronal differentiation of P19 cells. Following induction by retinoic acid, cells form embryonic bodies and then undergo neuronal differentiation, which is complete after 8 and 9 days. Immunochemical staining revealed that B2BKR protein expression was below detection limits in nondifferentiated P19 cells but increased during the course of neuronal differentiation and peaked on days 8 and 9. Measurement of [Ca(2+)](i) in the absence and presence of bradykinin showed that most undifferentiated cells are unresponsive to bradykinin application, but following differentiation, P19 cells express high molecular weight neurofilaments, secrete bradykinin into the culture medium, and respond to bradykinin application with a transient increase in [Ca(2+)](i). However, inhibition of B2BKR activity with HOE-140 during early differentiation led to a decrease in the size of embryonic bodies formed. Pretreatment of differentiating P19 cells with HOE-140 on day 5 resulted in a reduction of the calcium response induced by the cholinergic agonist carbamoylcholine and decreased expression levels of M1-M3 muscarinic acetylcholine receptors, indicating crucial functions of the B2BKR during neuronal differentiation.
authors.affiliation: Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Brazil.
authors.forename: Antonio Henrique B
authors.initials: AH
authors.lastname: Martins
authors.forename: Rodrigo R
authors.initials: RR
authors.lastname: Resende
authors.forename: Paromita
authors.initials: P
authors.lastname: Majumder
authors.forename: Marcella
authors.initials: M
authors.lastname: Faria
authors.forename: Dulce E
authors.initials: DE
authors.lastname: Casarini
authors.forename: Attila
authors.initials: A
authors.lastname: Tárnok
authors.forename: Walter
authors.initials: W
authors.lastname: Colli
authors.forename: João Bosco
authors.initials: JB
authors.lastname: Pesquero
authors.forename: Henning
authors.initials: H
authors.lastname: Ulrich
mesh_terms: D000818:Animals; D001483:Base Sequence; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000494:pharmacology; D065094:Bradykinin B2 Receptor Antagonists; D020013:Calcium Signaling / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000235:genetics; D015536:Down-Regulation / Q000187:drug effects; D015870:Gene Expression; D007704:Kininogens / Q000378:metabolism; D051379:Mice; D008959:Models, Neurological; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009474:Neurons / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D043782:Receptor, Bradykinin B2 / Q000235:genetics* / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000235:genetics
chemical_list: D065094:Bradykinin B2 Receptor Antagonists; D018076:DNA, Complementary; D007704:Kininogens; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D043782:Receptor, Bradykinin B2; D011976:Receptors, Muscarinic; C065679:icatibant; D002217:Carbachol; D001920:Bradykinin